Abstract
Background: Esophageal cancer (EC) comprises 1% of all diagnosed cancers in the USA. It is more common in other parts of the world. If there is distant metastasis, the relative survival rate is 6%. There are no standardized screening methods for EC. Case Presentation: We reported a four-year case of esophageal cancer, a P53-positive mutation with atypical distant metastasis to the cardiac and skeletal muscles. The patient was managed with multimodal therapy, including immunotherapy, which could have been a factor in prolonged survival. Conclusions: Distant metastases are typically seen postmortem, and with prolonged survival, we are able to find such unique metastases antemortem. Despite a history of negative scans, the patient’s ctDNA (circulating tumor DNA) remained positive, which was a better predictor of recurrence in this case. Future research is required to establish cost-effective screening methods and standardized treatments.
Original language | English (US) |
---|---|
Article number | 1146 |
Journal | Medicina (Lithuania) |
Volume | 60 |
Issue number | 7 |
DOIs | |
State | Published - Jul 16 2024 |
Keywords
- check point inhibitors
- ctDNA
- distant metastasis
- esophageal cancer
- immunotherapy
- Humans
- Middle Aged
- Male
- Circulating Tumor DNA/blood
- Heart Neoplasms/secondary
- Esophageal Neoplasms
- Muscle Neoplasms/secondary
- Aged
- Muscle, Skeletal
ASJC Scopus subject areas
- General Medicine